• (S)-Mephenytoin for CYP2C19 Organoids

  2026-08-18

  Use (S)-Mephenytoin as a quantitative CYP2C19 substrate to connect intestinal organoid biology with oxidative drug metabolism. This workflow emphasizes matrix controls, concentration bracketing, metabolite-resolved analysis, and troubleshooting for more interpretable pharmacokinetic studies.

• HNRNPU K181 Lactylation Rewires Cervical Cancer

  2026-08-18

  This Advanced Science study identifies HNRNPU lysine 181 lactylation as a metabolic signaling mechanism that stabilizes PHGDH transcripts and increases serine biosynthesis in cervical cancer. Its integrated computational, molecular, cellular, and in vivo evidence connects lactate accumulation with post-transcriptional control of tumor metabolism and suggests a pharmacologically tractable regulatory axis.

• H-Aggregated IR-1061 for NIR-II Cancer Therapy

  2026-08-17

  Yu et al. developed RR9-coated anionic liposomes that deliver IR-1061 and carboplatin while transferring the dye’s H-aggregated state to αvβ3-overexpressing tumor cell membranes. This design couples NIR-II fluorescence imaging with membrane-localized photothermal therapy and temperature-sensitive chemotherapy, providing a mechanistic framework for integrated cancer theranostics.

• Reactive Oxygen Species Assay Kit for OA Research

  2026-08-17

  Translate superoxide biology into actionable live-cell measurements with a DHE workflow tailored to chondrocytes, explants, and oxidative-stress models. This guide connects the APExBIO assay format with the PQQ–Nrf2–IGF1R findings in age-related osteoarthritis while emphasizing controls, normalization, and DHE-specific troubleshooting.

• Partial BACE Inhibition and Synaptic Transmission

  2026-08-16

  Satir et al. showed that moderate β-secretase inhibition can reduce amyloid β secretion by up to approximately 50% without disrupting synaptic transmission in cultured rat cortical neurons. The study supports a dose-sensitive prevention strategy in which BACE exposure is sufficient to limit amyloid β production but remains below levels associated with neuronal functional impairment.

• Regorafenib Suppresses Melanoma via RRM2

  2026-08-15

  A 2024 iScience study identifies RRM2 as a downstream mediator of Regorafenib activity in melanoma and connects its reduction with ERK/E2F3 pathway inhibition, apoptosis, and impaired malignant behavior. The work provides a mechanistic framework for studying Regorafenib in melanoma models while distinguishing pathway-level evidence from clinical treatment conclusions.

• SCH772984 for Reliable ERK1/2 Assays

  2026-08-14

  This scenario-driven guide explains how SCH772984 (SKU A3805) can improve the interpretation and reproducibility of ERK-dependent cell viability, proliferation, and cytotoxicity assays. It covers selectivity, dosing logic, DMSO stock preparation, pathway biomarkers, cross-domain radiosensitivity questions, and practical product-selection criteria.

• Fingolimod (FTY720) for Immune-Cell Workflows

  2026-08-14

  Fingolimod (FTY720) gives researchers a controllable way to study S1P-dependent lymphocyte trafficking, CNS signaling, and dose-related tumor-cell responses. This guide translates those mechanisms into practical assays and places them alongside, but not in place of, magnetic CAR-T-mimicking strategies for solid tumors.

• α-Amanitin Workflows for RNA Polymerase II Studies

  2026-08-13

  Use α-Amanitin as a controlled transcriptional perturbagen for RNA polymerase function assays, nascent RNA measurements, and developmental models. The most reliable workflows pair its rapid RNA polymerase II inhibition with viability, timing, and stage-matched controls that separate direct transcription effects from secondary cytotoxicity.

• Oleanolic Acid: Liposome Assay Workflows

  2026-08-13

  Build reproducible Oleanolic acid liposome studies around its lipophilic chemistry, inducible nitric oxide synthase induction, and immune-pathway readouts. A nanoparticle exclusion chromatography workflow adds a practical advantage by measuring free and encapsulated hydrophilic and lipophilic cargos in the same dual-loaded formulation.

• InstaBlue Protein Stain Solution: Practical Protocol

  2026-08-12

  InstaBlue Protein Stain Solution provides rapid Coomassie-based visualization of protein bands in polyacrylamide gels without routine fixation, washing, or destaining. It is appropriate for protein electrophoresis analysis and preparative band selection, but staining intensity should not be treated as a validated quantitative assay or universal sensitivity limit without laboratory-specific calibration.

• RNA Synthesis for Immune Pathway Discovery

  2026-08-12

  Mechanistic findings on SARS-CoV-2 nucleocapsid, GADD34, and IRF3 show why precisely defined RNA inputs matter in translational research. This article explains how the HyperScribe™ SP6 High Yield RNA Synthesis Kit supports reproducible transcript production, labeled probe workflows, RNA vaccine research, and functional validation while distinguishing experimental opportunity from clinical evidence.

• Bradford Protein Assay Kit: Practical Guide

  2026-08-11

  The Bradford Protein Assay Kit (SKU K4103) provides a rapid biochemical protein assay for measuring protein concentration in solution with a small sample volume. It is suited to enzyme assays, protein purification, and molecular biology workflows, but samples containing detergents or high concentrations of chaotropic agents require buffer exchange, dilution, or compatibility validation.

• Losartan Workflows for Vascular Research

  2026-08-11

  Build reproducible vascular assays around Losartan, from angiotensin II–driven signaling and smooth muscle proliferation to hypertension models. A mechanistic oncology study also shows how controlled Losartan delivery can remodel tumor mechanics, offering a carefully bounded extension for translational research.

• DMXAA (Vadimezan) Workflow for Tumor Vascular Studies

  2026-08-10

  Build more informative tumor-vascular assays with DMXAA (Vadimezan), combining endothelial injury, VEGFR2-related signaling, apoptosis, and tumor-cell readouts. This workflow distinguishes vascular disruption from vessel normalization and shows how to troubleshoot solubility, dosing, timing, and immune-context experiments.

14946 records 1/997 page Next 12345 下5页 Last page